OBJECTIVE: To investigate the population pharmacokinetics of mycophenolic acid (MPA) in adult kidney transplant recipients during the crucial first week after transplantation. METHODS: Data were collected from 117 patients. MPA plasma concentrations were determined at t=0, 1, 2, 3 and 4 h after mycophenolate mofetil dosing on days 3, 5 and 7. Population analysis was performed using NONMEM. Covariates screened were sex, age, body weight, serum creatinine, creatinine clearance, serum albumin, days of therapy, diabetes mellitus, organ source (live or cadaveric) and co-therapy (tacrolimus or cyclosporine). Final model validity was evaluated using 200 boot strapped samples from the original data. Bias and precision were determined through comparison of observed and predicted concentrations. RESULTS: Individual concentration-time profiles showed evidence of an absorption lag time and enterohepatic recirculation of MPA in some patients on some occasions. The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%). CL/F decreased significantly with increasing serum albumin (1.42 l/h reduction in total plasma CL/F with each 1 g/l increase in albumin) and was 27% greater in patients receiving cyclosporine than in those receiving tacrolimus. Evaluation of the final model showed close agreement between pairs of boot strapped and final model parameter estimates (all differences <7%). Predictions were non-biased (0.11 mg/l) but imprecise (2.8 mg/l). CONCLUSION: Population pharmacokinetic parameters for MPA were determined. These can be used to achieve specific target MPA concentrations or areas under the concentration-time curve.
OBJECTIVE: To investigate the population pharmacokinetics of mycophenolic acid (MPA) in adult kidney transplant recipients during the crucial first week after transplantation. METHODS: Data were collected from 117 patients. MPA plasma concentrations were determined at t=0, 1, 2, 3 and 4 h after mycophenolate mofetil dosing on days 3, 5 and 7. Population analysis was performed using NONMEM. Covariates screened were sex, age, body weight, serum creatinine, creatinine clearance, serum albumin, days of therapy, diabetes mellitus, organ source (live or cadaveric) and co-therapy (tacrolimus or cyclosporine). Final model validity was evaluated using 200 boot strapped samples from the original data. Bias and precision were determined through comparison of observed and predicted concentrations. RESULTS: Individual concentration-time profiles showed evidence of an absorption lag time and enterohepatic recirculation of MPA in some patients on some occasions. The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%). CL/F decreased significantly with increasing serum albumin (1.42 l/h reduction in total plasma CL/F with each 1 g/l increase in albumin) and was 27% greater in patients receiving cyclosporine than in those receiving tacrolimus. Evaluation of the final model showed close agreement between pairs of boot strapped and final model parameter estimates (all differences <7%). Predictions were non-biased (0.11 mg/l) but imprecise (2.8 mg/l). CONCLUSION: Population pharmacokinetic parameters for MPA were determined. These can be used to achieve specific target MPA concentrations or areas under the concentration-time curve.
Authors: Lutz T Weber; Maria Shipkova; Victor W Armstrong; Natalie Wagner; Ekkehard Schütz; Otto Mehls; Lothar B Zimmerhackl; Michael Oellerich; Burkhard Tönshoff Journal: J Am Soc Nephrol Date: 2002-03 Impact factor: 10.121
Authors: L T Weber; T Lamersdorf; M Shipkova; P D Niedmann; M Wiesel; L B Zimmerhackl; A Staskewitz; E Schütz; O Mehls; M Oellerich; V W Armstrong; B Tönshoff Journal: Ther Drug Monit Date: 1999-10 Impact factor: 3.681
Authors: L T Weber; M Shipkova; T Lamersdorf; P D Niedmann; M Wiesel; A Mandelbaum; L B Zimmerhackl; E Schütz; O Mehls; M Oellerich; V W Armstrong; B Tönshoff Journal: J Am Soc Nephrol Date: 1998-08 Impact factor: 10.121
Authors: Bronwyn A Atcheson; Paul J Taylor; Carl M J Kirkpatrick; Stephen B Duffull; David W Mudge; Peter I Pillans; David W Johnson; Susan E Tett Journal: Ther Drug Monit Date: 2004-06 Impact factor: 3.681
Authors: Reinier M van Hest; Teun van Gelder; René Bouw; Timothy Goggin; Robert Gordon; Richard D Mamelok; Ron A Mathot Journal: Br J Clin Pharmacol Date: 2007-01-03 Impact factor: 4.335
Authors: Catherine M T Sherwin; Anna Carmela P Sagcal-Gironella; Tsuyoshi Fukuda; Hermine I Brunner; Alexander A Vinks Journal: Br J Clin Pharmacol Date: 2012-05 Impact factor: 4.335
Authors: Flora T Musuamba; Michel Mourad; Vincent Haufroid; Martine De Meyer; Arnaud Capron; Isabelle K Delattre; Roger K Verbeeck; Pierre Wallemacq Journal: Br J Clin Pharmacol Date: 2013-05 Impact factor: 4.335